BioCentury | Apr 3, 2021
Product Development

Target diversity in the CAR NK and CAR NKT pipeline: Data Byte

...with CAR T cells on efficacy in blood cancers.More recently, ImmunityBio Inc. (NASDAQ:IBRX), which completed its merger with NantKwest Inc....
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...CAR NK cell therapies. Early clinical data from NantKwest Inc....
BioCentury | Jan 15, 2021
Product Development

Jan. 14 Quick Takes: Pancreatic cancer data lifts NantKwest; plus NIH-Alkermes, Abbott, Inzen

...By BioCentury Staff NantKwest Inc. (NASDAQ:NK) rose $3.01 (20%) to $17.79 Thursday after announcing positive interim data...
...Herrmann would succeed founding CEO Douglas Cole, the company’s chairman and a Flagship managing partner. BC Staff NantKwest Inc. Abbott...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...milestones; the company is eligible for £336 million in additional milestones, plus royalties.ImmunityBio merges with NantKwest...
...candidate meets in Phase IIIImmunotherapy company ImmunityBio Inc. will reverse-merge with NK cell therapy developer NantKwest Inc....
...will see ImmunityBio shareholders own about 72% of the combined company. The two biotechs were already testing NantKwest’s...
BioCentury | Dec 1, 2020
Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

...SZSE:002294), which led Viracta's series C round in 2018, holds rights in China to the combination. NantKwest Inc....
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...clinical research unit and director of Montreal Neurological Hospital’s ALS global center of excellence. Richard Adcock joined NantKwest Inc....
...Pharmaceuticals Inc. (NASDAQ:CYCC) as SVP and CMO. He was VP, hematology and oncology at ArQule Inc. Danielle Golovin NantKwest Inc. Seres...
BioCentury | Aug 6, 2020
Product Development

BioNTech testing separate mRNA vaccine variant in Chinese trial, closes supply deal with Canada

...IND to FDA to begin Phase I testing of a COVID-19 vaccine it’s developing with NantKwest Inc....
...Staff Writer and Sandi Wong, Assistant Editor Aviptadil (RLF-100) BNT162b1 BNT162b2 Relief Therapeutics Holding S.A. NeuroRx Inc. Clinical Reference Laboratory Inc. ImmunityBio Inc. NantKwest Inc. Pfizer...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

...flow to biotechs with at least four companies pricing offerings since Wednesday’s close. They include NantKwest Inc....
...million. Targets Cbl-b - Casitas B cell lymphoma-b BioCentury Staff Nurix Therapeutics Inc. Hutchison China MediTech Ltd. Enterome Bioscience S.A. NantKwest Inc. Castle...
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

...emergencies. Manufacturing continues to be a rate-limiting factor for COVID-19 countermeasures. Abivax S.A. (Euronext:ABVX) and NantKwest Inc....
...adjuvant is used in Dynavax’s marketed HBV vaccine, Heplisav-B. Funding for Abivax, more manufacturing for NantKwest...
...downregulates inflammatory cytokines. Be The Match BioTherapies will provide cryopreserved donor stem cell material for NantKwest Inc....
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

...to develop allogeneic NK cell therapies including CAR NK cells, and early clinical data from NantKwest Inc....
Items per page:
1 - 10 of 65
BioCentury | Apr 3, 2021
Product Development

Target diversity in the CAR NK and CAR NKT pipeline: Data Byte

...with CAR T cells on efficacy in blood cancers.More recently, ImmunityBio Inc. (NASDAQ:IBRX), which completed its merger with NantKwest Inc....
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...CAR NK cell therapies. Early clinical data from NantKwest Inc....
BioCentury | Jan 15, 2021
Product Development

Jan. 14 Quick Takes: Pancreatic cancer data lifts NantKwest; plus NIH-Alkermes, Abbott, Inzen

...By BioCentury Staff NantKwest Inc. (NASDAQ:NK) rose $3.01 (20%) to $17.79 Thursday after announcing positive interim data...
...Herrmann would succeed founding CEO Douglas Cole, the company’s chairman and a Flagship managing partner. BC Staff NantKwest Inc. Abbott...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...milestones; the company is eligible for £336 million in additional milestones, plus royalties.ImmunityBio merges with NantKwest...
...candidate meets in Phase IIIImmunotherapy company ImmunityBio Inc. will reverse-merge with NK cell therapy developer NantKwest Inc....
...will see ImmunityBio shareholders own about 72% of the combined company. The two biotechs were already testing NantKwest’s...
BioCentury | Dec 1, 2020
Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

...SZSE:002294), which led Viracta's series C round in 2018, holds rights in China to the combination. NantKwest Inc....
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...clinical research unit and director of Montreal Neurological Hospital’s ALS global center of excellence. Richard Adcock joined NantKwest Inc....
...Pharmaceuticals Inc. (NASDAQ:CYCC) as SVP and CMO. He was VP, hematology and oncology at ArQule Inc. Danielle Golovin NantKwest Inc. Seres...
BioCentury | Aug 6, 2020
Product Development

BioNTech testing separate mRNA vaccine variant in Chinese trial, closes supply deal with Canada

...IND to FDA to begin Phase I testing of a COVID-19 vaccine it’s developing with NantKwest Inc....
...Staff Writer and Sandi Wong, Assistant Editor Aviptadil (RLF-100) BNT162b1 BNT162b2 Relief Therapeutics Holding S.A. NeuroRx Inc. Clinical Reference Laboratory Inc. ImmunityBio Inc. NantKwest Inc. Pfizer...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

...flow to biotechs with at least four companies pricing offerings since Wednesday’s close. They include NantKwest Inc....
...million. Targets Cbl-b - Casitas B cell lymphoma-b BioCentury Staff Nurix Therapeutics Inc. Hutchison China MediTech Ltd. Enterome Bioscience S.A. NantKwest Inc. Castle...
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

...emergencies. Manufacturing continues to be a rate-limiting factor for COVID-19 countermeasures. Abivax S.A. (Euronext:ABVX) and NantKwest Inc....
...adjuvant is used in Dynavax’s marketed HBV vaccine, Heplisav-B. Funding for Abivax, more manufacturing for NantKwest...
...downregulates inflammatory cytokines. Be The Match BioTherapies will provide cryopreserved donor stem cell material for NantKwest Inc....
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

...to develop allogeneic NK cell therapies including CAR NK cells, and early clinical data from NantKwest Inc....
Items per page:
1 - 10 of 65